Watson Pharmaceuticals Inc. said the Food and Drug Administration have asked for additional information on the company's new, long-term dose version of its prostate cancer drug, Trelstar, before the agency grants an approval.

Watson Pharmaceuticals announced Tuesday that its drug Gelnique has been approved by the FDA for the treatment of overactive bladder. Gelnique, oxybutynin chloride gel 10%, is the first topical treatment for the condition overactive bladder, which causes uncontrollable urination.

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, has notified that its unit, Watson Laboratories, Inc. has received final nod from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for desogestrel/ethinyl estradiol and ethinyl estradiol tablets USP, 0.15 mg / 0.02 mg.